CS-162mixed
Fevertree Drinks plc (Fever-Tree), London-based premium mixer brand listed on AIM, which outsources its bottling
US expansion with local US bottling, followed by a margin-rebuild programme for the supply chain and the hand-over of US production and distribution to Molson Coors (2019-2025)
- Region
- Western Europe, North America
- Country
- United Kingdom, United States
- Industry
- Food and Beverage Manufacturing
- Functions
- Supply Chain & Logistics, Procurement & Strategic Sourcing, Manufacturing & Production, Finance & FP&A, Sales & Revenue Operations
- Topics
- Margins are eroding despite revenue; Supply chain disruption has made the network fragile; Supplier inflation and procurement leakage are unsustainable; Energy, resource or climate exposure undermines economics
- Starting situation
- New initiative
- Period
- 2019–2025
- Last verified
- 5 November 2026
Executive summary
Fever-Tree, a London mixer brand that owns no factories and has its drinks bottled by partners, set out in 2018-2019 to grow in the United States and to bottle there rather than ship glass bottles across the Atlantic [C01, C02, C05]. US sales nearly tripled in five years [C01, C19].
The supply chain did not keep pace. Glass, energy and freight costs rose, US bottling ramped slowly, the West Coast contract was not renewed, and gross margin fell from 50.5% to 32.1% in four years [C01, C11, C14, C15]. In 2025 the company handed US production, distribution and sales to Molson Coors, and most US product was still made in Britain [C17, C22].
The numbers that matter: US revenue £47.6m (2019) to £128.0m (2024) [C01, C19]; adjusted EBITDA £77.0m (2019) to £30.5m (2023) and £50.7m (2024) [C01, C14, C19]. The lesson: an asset-light brand that moves production to a new market must secure the co-packing capacity and the cost base there before demand outruns them.
Outcome: mixed
Documented shortfalls or reversals sit alongside documented gains. For example: an initial failure later recovered, or a strategic goal met while a major adverse event in the same programme was recorded.
Basis of the outcome
Gains: US revenue rose from £47.6m (2019) to £128.0m (2024), making the US the largest region, and the brand became the leading US tonic by value at retail (S01, S03, S13). Shortfalls: gross margin fell from 50.5% (2019) to 32.1% (2023) and adjusted EBITDA from £77.0m to £30.5m (S01, S09); 2023 guidance was cut from £36-42m to about £30-36m (S08); the March 2024 guidance of an adjusted EBITDA margin of about 15% and a gross-margin gain of about 600bps ended at 13.7% and 540bps (S09, S13). The US bottling network was cut back: the West Coast contract was not renewed (S09), US stock affected by production issues was quarantined and fully provided for (S07), and in 2025 most US product was made in Britain after US production and distribution passed to Molson Coors (S12, S15). Documented gains alongside documented shortfalls and a reversal meet the mixed criterion.
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | Revenue | £260.5m | 2019 | audited_filing |
| Before | US revenue | £47.6m | 2019 | audited_filing |
| Before | Gross margin | 50.5% | 2019 | audited_filing |
| Before | Adjusted EBITDA | £77.0m | 2019 | audited_filing |
| During | West Coast line in production | Dec 2020 | 2020 | company_reported |
| During | Profit guidance cut | £63m-66m to £37.5m-45m | Jul 2022 | press_reported |
| During | US inventory provided for | £3.3m | H1 2023 | company_reported |
| After | Gross margin (low point) | 32.1% | 2023 | audited_filing |
| After | Adjusted EBITDA (low point) | £30.5m | 2023 | audited_filing |
| After | US revenue | £128.0m | 2024 | audited_filing |
| After | US share of group profit | about 2% | 2023 | press_reported |
| After | Molson Coors stake | 8.5% for £71m | Jan 2025 | multiple_independent |
- audited_filing
- A figure in audited financial statements, such as an annual report's financial statements or a 10-K.
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- press_reported
- A journalist's own reporting.
- multiple_independent
- Two or more independent sources agree.
Practices this case bears on
- SupportsGate every go-live on measured readiness, not on the calendar BP-001
- SupportsMake a few quantified, dated commitments, publish them, and report against them, including the misses BP-004
- SupportsRoll out operational and system change in waves, each proven before the next BP-006
- SupportsOutsource only what does not differentiate, and keep the capability to specify, integrate and replace partners BP-017
- SupportsAnnounce only targets the evidence supports, build synergy estimates from shared data, and re-base them openly BP-033
- SupportsJudge growth and customer strategies by unit economics and customer behaviour, not by totals or activity BP-037
- SupportsWrite exit and pause criteria at approval, and treat impairments as triggers to re-test the strategy BP-042
- SupportsRe-plan openly when the facts change, rather than defending the old timetable BP-043
- SupportsMeasure and report each business separately before deciding its future BP-051
- SupportsPlan on the downside: assume the legacy business declines faster and the cycle turns, and have the cost playbook ready BP-054
- SupportsMap critical dependencies several tiers deep, buffer what cannot be re-sourced, and decide who pays for resilience BP-064
- SupportsUse partnerships to buy speed or share risk, but price in their execution risk and plan for some to fail BP-070
- SupportsGrow by a multiple only after the operating system has been proven at the new scale BP-072
Sources
- S01 Fevertree Drinks plc: Preliminary Results (year to 31 December 2019) · Fevertree Drinks plc, London Stock Exchange RNS (via lse.co.uk), 2020-04-22 · accessed 2026-11-04
- S02 Fevertree Drinks plc: FY20 Preliminary Results to 31 December 2020 · Fevertree Drinks plc, London Stock Exchange RNS (via lse.co.uk), 2021-03-18 · accessed 2026-11-04
- S03 Fevertree Drinks plc: FY21 Preliminary Results to 31 December 2021 · Fevertree Drinks plc, London Stock Exchange RNS (via lse.co.uk), 2022-03-16 · accessed 2026-11-04
- S04 Fever-Tree slashes profit forecast over surging costs and staff shortages · Jacqui Parr, Grocery Gazette, 2022-07-15 · accessed 2026-11-04
- S05 Fever-Tree profit falls 30% after being hit by rising costs · Mark Wembridge, The Irish Times (Financial Times content), 2022-09-13 · accessed 2026-11-04
- S06 Fevertree Drinks plc: FY22 Preliminary Results to 31 December 2022 · Fevertree Drinks plc, Investegate (RNS), 2023-03-22 · accessed 2026-11-04
- S07 Fevertree Drinks plc: Fever-Tree FY23 Interim Results - Replacement · Fevertree Drinks plc, London Stock Exchange RNS (via lse.co.uk), 2023-09-12 · accessed 2026-11-04
- S08 Fever-Tree cuts revenue, profit forecasts · Dean Best, Just Drinks, 2023-09-12 · accessed 2026-11-04
- S09 Fevertree Drinks plc: FY23 Preliminary Results to 31 December 2023 · Fevertree Drinks plc, London Stock Exchange RNS (via lse.co.uk), 2024-03-26 · accessed 2026-11-04
- S10 ii view: confident Fevertree shrugs off profit slump · Keith Bowman, interactive investor, 2024-03-26 · accessed 2026-11-04
- S11 Fever-Tree sells £71m stake to Molson Coors · William Dodds, Food Manufacture, 2025-01-30 · accessed 2026-11-04
- S12 Fevertree to launch share buyback as part of US distribution deal · Emily Parsons (Alliance News), Morningstar UK (Alliance News), 2025-01-30 · accessed 2026-11-04
- S13 Fevertree Drinks FY24 Preliminary Results · Fevertree Drinks plc, James Sharp & Co (copy of the RNS), 2025-03-25 · accessed 2026-11-04
- S14 Fever-Tree confident on FY25 outlook despite US tariffs · Yasmeen Louis, Grocery Gazette, 2025-06-05 · accessed 2026-11-04
- S15 Fevertree Drinks' first-half pretax profit falls 15% on US margin pressure · Reuters, RTÉ News (Reuters), 2025-09-11 · accessed 2026-11-04
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 5 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

